MET and lung carcinoma: Interrogation of the predicted TK-substrate network generated biologically meaningful hypotheses, followed by experimental validations illustrating the effectiveness of predicted kinase inhibitor combination, EGFR and c-MET combination inhibitors, in treating lung cancer cell lines.